Improvement of visuo-spatial function assessed by RCPM in dementia with Lewy bodies by donepezil treatment
Yuta Yoshino 1, Takaaki Mori 1*, Taku Yoshida 1, Yasutaka Toyota 2, Hideaki Shimizu 1, Jun-ichi Iga 1, Shusaku Nishitani 2, Shu-ichi Ueno 1
1Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan, 2Department of Neuropsychiatry, Zaidan Niihama Hospital, 13-47, Matsubara, Niihama, Ehime, 792-0828, Japan
Received: October 21, 2016; Revised: December 12, 2016; Accepted: December 20, 2016; Published online: December 20, 2016.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Background and Aims: Donepezil is used to improve cognitive impairment of dementia with Lewy bodies (DLB). Visuo-spatial dysfunction is a well-known symptom of DLB. Non-verbal Raven’s Colored Progressive Matrices (RCPM) were used to assess both visual perception and reasoning ability in DLB subjects treated with donepezil.
Methods: 21 DLB patients (mean age, 78.7 ± 4.5 years) were enrolled. RCPM assessment was performed at the time of starting donepezil and within one year after starting donepezil.
Results: There were significant improvements of RCPM in the total scores between one year donepezil treatment (p = 0.013), in both Set A score (p = 0.002) and Set AB score (p = 0.015), but trend in the Set B score (p = 0.083).
Conclusions: Donepezil is useful for improving visuo-spatial impairment in DLB, but not for problem-solving impairment.
Keywords: Dementia with Lewy Bodies, Cholinesterase inhibitor, Raven’s Colored Progressive Matrices, visuo-spatial function